This unique book offers a methodical exploration of biological, social, and ethical topics on the treatment (or lack thereof) of psychotic brain disease. Part I provides an empirical engagement with neuroscience and covers the neurobiology and pharmacology of schizophrenia, providing the reader with a current understanding of the disease. Topic areas include anosognosia, community treatments, and early intervention. Part II looks at international policy approaches to schizophrenia featuring topics such as the policy, funding, and historical elements contributing to frequently misguided approaches to severe brain disease, and it explains why some societies won't/can't support human beings with psychotic disease. Part III focuses on neuroethics and asks: 'What is right?' through chapters discussing the concepts of consciousness and free will, as well as the principles of nonmaleficence, beneficence, autonomy, and justice. Collectively the comprehensive approach of this book allows the reader to gain a full understanding of the ethical and clinical complexities in treating schizophrenia.
Muu info
A scientific exploration of biological, social, and ethical topics related to the treatment (or lack thereof) of psychotic disease.
Part I. Neuroscience:
1. The story of schizophrenia: liberty over life;
2. What is the neurobiology of schizophrenia?;
3. What is schizophrenia
symptomatology;
4. Assessment and treatment of anosognosia in schizophrenia;
5. Anosognosia in schizophrenia;
6. 'How antipsychotics work in
schizophrenia: a primer on mechanisms';
7. Do antipsychotics work in people
with schizophrenia? A review of outcomes and effect sizes;
8. Do
antipsychotic medications work: an exploration using competency to stand
trial as the functional outcome;
9. When do psychiatric interventions work?
An argument for using functional outcomes when evaluating the effectiveness
of treating schizophrenia;
10. Medications for psychosis in people with
Schizophrenia: what happens if you take them and what happens if you don't?;
11. Assisted outpatient treatment: are court ordered antipsychotic
medications effective?;
12. Forensic assertive community treatment: an
emerging best practice;
13. Does compulsory community treatment for
discharged forensic hospital patients work? The recent evidence base;
14.
Early intervention for schizophrenia: a pathway to improved clinical
outcomes;
15. 'Cardiometabolic disorders in persons living with
schizophrenia: the right to equality'; Part II. International Policy
Perspectives:
16. Failure to treat: an American policy perspective;
17. The
Italian general psychiatry and forensic psychiatry treatment model: a unique
story;
18. Liberty or life: mental health care in Australia;
19. Liberty or
life: the Aotearoa New Zealand perspective;
20. Autonomy and compulsory care
in the Netherlands;
21. Canadian mental health laws: a review of involuntary
admission and treatment pending appeal;
22. The current situation of
treatment for patients suffering from schizophrenia in the Austrian forensic
system;
23. Interventions for the unhoused individual with schizophrenia: a
civilized plan;
24. What role did serious mental illness play in Jackson
Pollock's drip paintings? Abstract expressionism and possible links to
serious mental illness and to encrypted images (Polloglyphs);
25. The
behavioral healthcare continuum in the United States: what should it look
like and how we can pay for it; Part III. Neuroethics:
26. A unified
understanding of the human mind-a neuroethical perspective: tracing the
evolution in western thought and the integration with neuroscience,
psychology, psychiatry, and relational dimensions;
27. A neuroethical
approach to human life, identity, and liberty of schizophrenic patients;
28.
Neuroethics and treatment without consent;
29. Advance directives in patients
with schizophrenia;
30. Dignity restored: the power of treatment first;
31.
Four principles of bioethics in cases of anosognosia;
32. Complexities of
competency and informed consent as applied to individuals with symptoms of
Anosognosia;
33. Evidence-based treatment for schizophrenia: a personal
perspective;
34. Inmate mental health assistants: an emerging best practice
for carceral settings;
35. Remarks of father Alberto Carrara to the American
Psychiatry Association May 2025 Father.
Katherine Warburton is Associate Clinical Professor at the University of California, Davis, and Statewide Medical Director and Deputy Director of Clinical Operations at the California Department of State Hospitals. Stephen M. Stahl is Distinguished Clinical Professor of Psychiatry and Neuroscience at the University of California Riverside, Adjunct Professor of Psychiatry at the University of California, San Diego, and an Honorary Fellow in Psychiatry at the University of Cambridge. He also serves as Senior Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals.
